MetLife Investment Management LLC Acquires New Position in Enanta Pharmaceuticals, Inc. $ENTA

MetLife Investment Management LLC acquired a new stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 13,079 shares of the biotechnology company’s stock, valued at approximately $72,000. MetLife Investment Management LLC owned approximately 0.06% of Enanta Pharmaceuticals at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ENTA. US Bancorp DE purchased a new stake in Enanta Pharmaceuticals during the 1st quarter valued at about $36,000. GAMMA Investing LLC purchased a new stake in Enanta Pharmaceuticals during the 1st quarter valued at about $40,000. Tower Research Capital LLC TRC grew its stake in Enanta Pharmaceuticals by 46.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 2,274 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in Enanta Pharmaceuticals during the 4th quarter valued at about $66,000. Finally, Velan Capital Investment Management LP purchased a new stake in Enanta Pharmaceuticals during the 4th quarter valued at about $75,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ENTA. JMP Securities upped their price objective on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 12th. Wall Street Zen raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, June 22nd. HC Wainwright assumed coverage on shares of Enanta Pharmaceuticals in a report on Monday, July 28th. They set a “buy” rating and a $20.00 price target for the company. Finally, Westpark Capital assumed coverage on shares of Enanta Pharmaceuticals in a report on Tuesday, September 2nd. They set a “buy” rating and a $24.00 price target for the company. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $22.25.

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA opened at $8.33 on Thursday. The stock has a market capitalization of $178.10 million, a P/E ratio of -1.93 and a beta of 0.84. The company has a 50 day moving average price of $7.83 and a 200 day moving average price of $6.80. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $13.37.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.40. The firm had revenue of $18.31 million during the quarter, compared to analysts’ expectations of $16.21 million. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. Research analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.